发明名称 Reverse two-hybrid method
摘要 The reverse two-hybrid method has been designed to provide a practical and efficient means of utilizing yeast cell-based assays to screen for molecules that can inhibit protein-protein interactions of interest. Existing two-hybrid systems involve reconstitution in yeast of a transcriptional activator that drives expression of a "reporter" gene such as HIS3 or lacZ. Attempts to utilize these existing systems for drug discovery would necessarily involve screening for molecules that interfere with the transcriptional read-out, and would be subject to detecting any compound that non-specifically interfered with transcription. In addition, since currently used reporter genes encode long-lived proteins, the assay would have to be performed over a lengthy time period to allow for decay of the preexisting reporter proteins. Any compound that would be toxic to yeast over this time period would also score as a "hit". The reverse two-hybrid interaction will avoid both of these pitfalls by driving the expression of a relay gene, such as the GAL80 gene, which encodes a protein that binds to and masks the activation domain of a transcriptional activator, such as Gal4. The reporter genes, which will provide the transcriptional read-out (HIS3 or lacZ), are dependent upon functional Gal4 for expression. Only when the level of Gal80 masking protein is reduced by interfering with the two-hybrid interaction will Gal4 function as a transcriptional activator, providing a positive transcriptional read-out for molecules that inhibit the two-hybrid protein-protein interaction. An important feature of the reverse two-hybrid system is that the basal level and half-life of the relay protein, Gal80, can be fine-tuned to provide maximum sensitivity.
申请公布号 AU2779095(A) 申请公布日期 1995.10.17
申请号 AU19950027790 申请日期 1995.03.28
申请人 ONYX PHARMACEUTICALS, INC. 发明人 JAMES R. ERICKSON;SCOTT POWERS
分类号 C07K14/395;C12N15/10;C12Q1/68 主分类号 C07K14/395
代理机构 代理人
主权项
地址